An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Baseline Characteristics Reported from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH Spruce Biosciences, Inc., today reported baseline characteristics of patients enrolled in the CAHmelia-203 and CAHmelia-204 clinical studies of tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH)....
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency On December 19, Ascendis Pharma announced positive topline results from foresiGHt, its Phase 3 randomized, parallel-arm, placebo-controlled (double-blind) and active-controlled...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves Lilly’s Zepbound™ (tirzepatide) for Chronic Weight Management On November 8, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide)... An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information.* New Clinical Data Point to Use of GlycoMark as Biomarker of SGLT-2 Diabetes Drug Effectiveness and Compliance Precision Diabetes, Inc. announces new studies that show that the GlycoMark blood test, which measures 1,5-anhydroglucitol, may be useful for evaluating short-term effectiveness and assessing...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves sNDA for Pediatric Achondroplasia Drug On October 20, the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for VOXZOGO® (vosoritide) to increase linear growth in pediatric patients with achondroplasia with open epiphyses (growth plates)....
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Spruce Biosciences Focuses on CAH in Clinical Trial On October 18, Spruce Biosciences, Inc., a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, announced completion of target enrollment of 72...
